A patient in our center who underwent IVF had good ovulation, good quality embryos, good uterine conditions, normal endometrial morphology and thickness, but no pregnancy was obtained after 3 transfers. However, the patient failed to achieve pregnancy after 3 transfers. After screening for closed antibodies, several of the indicators were found to be abnormal, and a second transfer cycle with medication resulted in a pregnancy. Recurrent miscarriage refers to two or more consecutive spontaneous miscarriages, with a prevalence of about 5% among women of childbearing age. The former occurs at the stage of embryo implantation, while the latter occurs when the embryo implants but fails to continue its development. Both diseases involve a variety of etiologies such as pathological changes in either mother or fetus during implantation or early pregnancy or immune abnormalities at the maternal-fetal interface, and have much in common in terms of diagnosis and treatment. Since these two diseases are common causes of infertility and low IVF-ET pregnancy rate, and many patients need to be examined and treated, our center, after thorough preparation and with the support of hospital leaders and relevant departments, will officially open a special clinic for “Repeated Failed Clotting and Habitual Miscarriage” this month. We will provide comprehensive diagnosis and effective treatment for infertility caused by these two diseases. One of the special features of this special clinic is the detection of closed antibody and immunotherapy. Sequestering antibodies are antibodies produced by maternal exposure to paternal antigens during pregnancy, which can bind to placental cell surface antigens, thus blocking maternal cytotoxic T cells from launching immune attacks on the embryo and playing a role in protecting the fetus and maintaining pregnancy. Scholars at home and abroad agree that a large proportion of recurrent miscarriages are caused by the maternal inability to recognize paternal antigens and produce protective responses. Clinical use of lymphocyte immunotherapy with the partner induces the maternal alloimmune response, resulting in the appearance of confinement antibodies and microlymphocytotoxic antibodies, which makes the maternal immune system less likely to produce immune attacks on the fetus and allows the pregnancy to continue. In clinical practice, it has been found that closed antibody detection and treatment is also a good treatment for recurrent failure to conceive. The clinic can perform karyotype analysis of embryos, male semen analysis, maternal endocrine and metabolic disease testing, immune antibody testing, coagulation testing, and other tests to determine the cause of more than 70% of cases and provide effective treatment, which can help increase the IVF pregnancy rate, reduce the incidence of recurrent miscarriage, increase the final live birth rate, and reduce It helps to improve the IVF pregnancy rate, reduce the recurrence of miscarriage, increase the final live birth rate, and reduce the mental and physical pain of patients.